Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Coilly

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
JHEP Reports : Innovation in Hepatology|February 28, 2023
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosisFrançois Villeret, Sébastien Dharancy, Domitille Erard, et al.
Journal of Hepatology|July 9, 2024
Long-term outcome following liver transplantation of patients with ACLF grade 3Florent Artru, Sophie-Caroline Sacleux, Jose Ursic-Bedoya, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 28, 2016
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantationJérôme Dumortier, Vincent Leroy, Christophe Duvoux, et al.
Clinics and Research in Hepatology and Gastroenterology|March 14, 2021
Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patientsMario Altieri, Olivier Sérée, Thierry Lobbedez, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2017
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT studySébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, et al.
Hepatology (Baltimore, Md.)|April 11, 2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver TransplantationPauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, et al.
Journal of Hepatology|June 6, 2016
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT studyAudrey Coilly, Claire Fougerou-Leurent, Victor de Ledinghen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2019
Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter StudyNassim Kamar, Florence Abravanel, Patrick Behrendt, et al.
Gastroenterology|December 11, 2020
Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European StudyLuca S Belli, Constantino Fondevila, Paolo A Cortesi, et al.
Journal of Hepatology|April 11, 2019
Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the differenceLina Mouna, Emilie Rossignol, Mariagrazia Tateo, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
JHEP Reports : Innovation in Hepatology|February 28, 2023
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosisFrançois Villeret, Sébastien Dharancy, Domitille Erard, et al.
Journal of Hepatology|July 9, 2024
Long-term outcome following liver transplantation of patients with ACLF grade 3Florent Artru, Sophie-Caroline Sacleux, Jose Ursic-Bedoya, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 28, 2016
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantationJérôme Dumortier, Vincent Leroy, Christophe Duvoux, et al.
Clinics and Research in Hepatology and Gastroenterology|March 14, 2021
Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patientsMario Altieri, Olivier Sérée, Thierry Lobbedez, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 13, 2017
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT studySébastien Dharancy, Audrey Coilly, Claire Fougerou-Leurent, et al.
Hepatology (Baltimore, Md.)|April 11, 2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver TransplantationPauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, et al.
Journal of Hepatology|June 6, 2016
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT studyAudrey Coilly, Claire Fougerou-Leurent, Victor de Ledinghen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2019
Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter StudyNassim Kamar, Florence Abravanel, Patrick Behrendt, et al.
Gastroenterology|December 11, 2020
Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European StudyLuca S Belli, Constantino Fondevila, Paolo A Cortesi, et al.
Journal of Hepatology|April 11, 2019
Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the differenceLina Mouna, Emilie Rossignol, Mariagrazia Tateo, et al.
Pageof 14